Upload
lyu-jh
View
57
Download
0
Embed Size (px)
Citation preview
1
8 3
() 1. 1 98
102 2 190 26 77
2 19 102 1 14 102 104
2
1 20 1 28
3 102 15 28 180 95
4 97 CPR+AED 222 1 5,000 36 AED CPR+AED 102 1 16 10200003971 (AED)AED
3
2.
1 9 17 24
2 13 8
3 15 21 28 24
() 1.
99 7 1101 78213 831
4
2. 101 39 1,325
3. 14 101 131 1 4,327
4. 102 (OSCE) 102 22
5. 101 16 45 103 1 1
6. 101 14
5
() 1. 101
14 5 31,485
2. 118 108 96 1 4,131 101 3 8,507 94 71.5% 100 5%
3. / 101 4 2 10% 658(HbA1c) 775/ 130/85 86
6
() 1.
101 22 292 101 56 5,186 4.31 42% 102 1 13 1,228
2. 97 7 499 1,696 95%100 1,211 96.12%101 1,221 96.8%102 1 86 97.7%99 27 100%100 40 97.5%101101 56 92.86%
3. 100 3,507 10 15.1 99 3,889 10 16.8 382 9.8% 99 2 10 100 12 101 1 12
7
3,461 100 46 1.3% 101 102 6
() 1. 101
198 9
2. 175 851
3. / 69
4. 102 1
5. 1 10
8
2 3
6. 101 12 28 102 2 1
7. 91 2012
() 1. 5 (33
25100
9
26) 11
2. 101 1 1 103 12 31 200 101 10 1 102 2 23 188 37 15 13 1,535
3.
4. 100
5.
6. () 1
10
24 98.7
2 () ()
7. 101 5 10 6 10
1 102 1 49 14 71%10
2 101622
3 101
11
4 101 67%
4 101 9 21 () 101 9 1 100 200 101 64%
5 150 30 60 102125
6 101 2 302 () 27,508 2,555.2
7 101 12 141,007 (101 4 ) 136,415 4,592
8 101 5 101 12 2,829 1,670 1,159
12
9 102 3,000 5,000 2
10 101 7-9
11 8 29
12 8
13 102
8. 1 101 6 4 6
2 95 101
3,728 3 100 69
13
2,488101 80102 13
4 102 () 9. 1 100 23 1
101 102 102
2 101 57 4 10 9 5 29
3 102
() 1. 102 1 8
2
2. 100 6 7
14
1 25
2 101 12 117 10 91 16 10 ()
3. 24 95 3 101 495 4,593
4. 15 ( 25 ) CDC 61%
5. 1 101
7 101 111 , 1 6,311 868284 102 11
2 101 3 101
15
11 101 3,689 1,775 1 5,826 102 7
4 101 102 16
5 1,943 ( 1,497 227 216 3)
6. (21 100 5 28 )(22) H1N1(22 100 )
7. (IRC) 7 100 1 101 12 7 8,602 10,731 8 9,333 19
16
14
8. () () () ()
9. 26102 3ISO
10. 102 6 ()()()()()()() IRC()
() 1. 1
101 12 282
2 101 12 207
17
3 101 12 191
2. 101 12 IC 36
3. 101 12 189 183
() 1. 1
HIS 101 12 55 ( 30 18 7 )
2 32 ( 23 9)(PACS)
18
3
100 19 101 6,906
2.
1 101 338 () 3
2 101 314 241 2 40
3 () 102 2 16 () 3 101 102 3,550
3. 101
19
86 101 6 5,296 1 4,078 10 4,16 2 9,517 1,904 9 1,968 1 600
4.
5. 101 401,600
6. 101 807 102 52 (27 )
7. 24 101 277 94.86%
20
101
8.
() 1. 1
2
()(22 )(63)(368 )
3 5 101
2. 1
21
99 101 1 157 52 2 157101 22
99 101 8,262 305 99 101 8,759 17,021
2 ()101 13 102 20
3. 1
97 2.3%98 5.7%99 16.3%100 21% 101 27%( 16%)97 101 11 3,202
22
100 6 1,675 97 3.5 101 6 4,733 100 1.1
101 9,737 3,332 CDR
2 101 311
4. 7 7 8 7 8 1 2 3 101 2 23 7 129 6 95
5.
1 (
23
)()101
2 101 102 6 1036
3 101 7 102 12 103 6
4
24
5 98 9 101 12 106 300
() 1. 99 4 1
99 3 604 101 12 206
2. ()101 12 18.58
3.
25
101 12 680 2.64%
4. 7 100 12 1 101 -0.36%
() 1. 1 100
4.39 4.17 5.01% 4 5,511 4 5,366 145 0.32%
2 101 1 11 (98 1 11 )4.39 4.13 5.92%(98 1 11)4 5,474 4 5,182 292 0.64%
26
3
2. 1
8 3 20 3 10071103 6 30 101 1 1 103 12 31 101 3 1
2 ()
3. 1 101
21.47
101620
27
57114C 6 43 12.83
0.572 8.527 9% 4 2 6 3% 9.099
101 1 1
2 101 3.2
3 100 8 RBRVS 37 100 9100 10 26 101 10 102
28
4 10250.552.22
4. (1)(2)(3) 3 101 12 387
() 1. 101 12
258 219 2. 1 101 12
3,589 2.14 13 31.8 4,755 2,274
2 101 4.3 3.53
29
3. 101 12 3,787 1.1
4. 1 99 10
101 12 43.4 20
2 101 6 4 101 12 14.1 4
5. (IDS)
1 48(42)
2 101 25 4-6
30
(1004.39101193.03)
() 1.
90 99 150 () 100 ()100 100 33,138 7.2 101 12 24 26% 8.29
2.
3. 98 12 101 193 46 101 0.12 9.9%
31
() 1. 100
2. 102 1 1
3. Health Technology Assessment, HTA 101 11 26 HTA
32
() 1. 10112572
40 2,363 242 () 160 91 102
2. 101 1,926 18 (14 22)
3. 101 12 61 637
4. 4LC/MS/MS
5. 101 1 12 50
() 1. 1 101 8 8 11
33
17 1 31 101 8 27 102 1 10
2 101 12 248 )10 11 98
2. 1 101
QSA 9 63.31% 101 9 13 12 983 815
2 101 9 6
34
101 9 12 101 9 20 101 9 12 11 20 33,550 99.8%
3 101 9 1111 18446
3. 1 101 12 45,0942 (
781 )101 37,899 100 27%
2 101 12 424
4. 1
http://fadenbook.fda. gov.tw/101 12 501 11,253
35
101 4 400
2 101 6 28 101 7 9
5. 1 101 1 18
101 8 9
2 100 7 21 101 7 21 () () 82
36
() 1. 1 (cGMP) 101 12
158 ( 10 3) 21( 146) GMP
2 PIC/S GMP 45 PIC/S GMP 102 1 1 PIC/S 43
3 (GMP) 101 12 GMP/QSD 3,596 14.7% 85.3%
2. 1 99-101 271
101 6
2 101 4 5 (REMS) 101 12
37
REMS 12 14 6 58
3 101 12 773 1,275 89 100%
4 101 12 80
5 99 (Global Harmonization Task ForceGHTF)(NCAR) 101 4 649 101 1,385 1,119 160
6 101 1,111 191 183 8 159 141 18 132 102 20 10 629 142 7 480
3. 6 101 6 27 3 4
38
4. 101 6 27
GMP GMP
5. 101 11 1
() 1. 101 10 15
(eCTD) 2. 101 12 7
3. 101 42 (approval letter)
4. 101
39
12 25 6
5. 101 11 29 (STED) 36
6. 22 17 2
7. 34 101 12 6 913 6 2 3 24 32 33.3%
8. WHO ICDRA
() 1.
101 1 6,216 202 1.25%
40
2. 101
18,22510016,6549.4%
() 1. 101 12
8,142 2 346 2 99 1 13.93% 101 12 4.71% 9.22%
2. 99 3 1,500 99 27.22% 101 12 1.76% 98 30.2% 101 14.4%
() 1. 101 827
2,318 345 159 364 280
2. 101 79 11 3 21 261
41
17 3. 101 121
507 99.6% 4. 101
331 271
5. GMP 101 49 GMP
6. 101 8 1 10 12 857
7. 101 300
8.
9. 101 9 5 62012
10. 101 9 14 16 16Last Year and This Year in Taiwan 2014 17 4
42
11. Journal of Traditional and Complementary MedicineJTCM 101 12 5 50
() 1. WHO101 9 24
102 2 16 3 15 9
2. 9 24 WHO
3. 10
4.
5. 101 9 28 10 3
43
6. 3
84
7.
() 1. 71
(101) 153 2 1.3(102) 3 131
2.
3. 71
4.
44
5.
101 5 14
6. 5
() 1. 101 1,273
751 503 7 5 2 1 (102) 3 13 15101 100 82.3 99 79.8101 207 7445302014 10 102 42 1718542008-2012 1538372030
45
2.
3. 101
4. 101 3 101 5 9
5. 101 4 5 8 2,490
6. 101 6
46
() 1. 94-100
35.6%
2. (DOTS)101 12,064 90%
3. X 101 5,513 100 4,842 99 3,874
4. (MDR) 96 5 100101 145
5.
() 1. 101 2 4,239
47
15-24 4,716 19.5 101 2,224 1,718 77%15-24 635 28.6
2. ()
3. 5
4. 101 10 0,198
5. 96 101 46 101 12,554
48
6. 101 11 21 () 928 415 1 101 11 24 4,000 333 91.39% 100
() 1. 101 7 1 102 3 13
412 35 (1,306 130 ) AH3
2. 101 11
3. 101 297 5,365 101 10 1 65 6 6 102 1 50-64
49
101 12 26 65 102 3 11 282.7 97.6%
4. 10-15% 101 12 1 102 3 31
5. 101 100 14
6. 101 1,247 H5N2 2.39 H5N2
7. 101 3 1 8 31 101
50
A/H5N1 9,761
() 1. 101
101 492
2. 102-104
3. 101 59 9()
4.
5. WHO 555
51
5 ( 5 )
() 1. 101 55
(PCV)(102) 3 2-5 PCV
2. 101 4 101 9 MMR Tdap-IPV
3. 75
52
() 1.
2. 101 12 649 100 3 3 96 101 12 7
() 1. 101100
186 94.04% 1 98.35%101 1-6 104 97%
2. 99 100 101 4 15 500 12 509 97.7% 374
53
66.8 13 2,430 91.0%
3. 101 1 12 5 1,825 1,399 23 3,118 99.7%3,600 10,697 3,887
4. 101 163 75.1%100 71.4% 100 45.6% (93 24%97 35.1% 2025 50%) 99 11 24 101 12 1,788 100%
5.
54
28 4 1 10 50 101 4 5 101 795 156 6 2 99 1.090100 1.079 16 3 12101 1.074 25 15
6. 101 17,088 774,38720-49
55
72,827
() 1. 4 5
101 1 12 35 1,845 96% 98%
2. 99 101 3 15 700 12 309 95.6%(175 )(134 ) 17 380 89.4% 216
3. 5 1 100 30 9,118 101 6 16 7,794 101 7 18 101 22 2,659 146
4. 7 7 99 103 1 1
56
98.3%100 100 80%100 1 1 98%101 1-6 55 7 84% 100
5. e101 44 5,903 2,221 39 Teens 9 4,044 113 / 120 2 1,750 61 64 521 msn 131
() 1. 40 64 3 155
65 1101 179 100 177
2. 101 101-102
57
3. 101 18 58.1% 43.6%
4. 101 20 33 1 8 2,917 3 8,543 5 8,802 90%
5. 101 Healthy Lifestyle Healthy Blood Pressure 1,014 887 1,989
6. 100-104101-103
7.
58
8. 101 524
9. 490101 186 22
10. 101 131 50 33 3,808 12 65 101 7 9 8,206 45 5,922
11. 101 65 87.1 101 50 69 51 50-69 101.265 269 101
59
1-10 4,574
12. 101 22 367 1,435 458 1,454 80% 75%
13. 199
101 12 38
2101 40
3 101 28 268
60
4101 4 11 20 WHO Working Group on HPH and Age-Friendly Health Care
14. WHO-100 9 101 20 101 22 APEC 101 8 28-29 2012 APEC APEC 101 9
61
10 4 101 12 1112 360
15. 101 22 1,905 7 4 3
() 1.
Alliance For Healthy Cities, AFHC 101 1011 AFHC 10 11 101
62
AFHC(Award for Creative Developments in Healthy Cities)
2. 1 101 12 93 WHO
2 101 WHO-HPH Recognition Project 21
3 101 4 11-13 2012 20 598 3
4 101 () 2
5 101 3 73 84
3. 101 18 142 ( 38.6
63
5
4. 94 101 28 101 12 19
5. 101 12 9,186 342
6. 1 3,699
101 214
64
(WHO IUHPE Mr.Ian YoungNoy S Kay Robert F. Valois Lawrence Harry St Leger ) 4 14 120 138
2 101 78
7. 1 101 6
9,345
2 100
8. 100 101 12 31
65
1726 101 632 ( 36.6%)237 101 1 10 1 867 57
() 1. 100 22
100 101 101 22 101 12 7,012 77 9,303 1,137 60 600
2. 368
3.
66
0800-367-100101 -
4. 1 18 100 65.1%
101 70.8%
2 100 22 1035 138 101
5. 1
2 101 18 142
67
() 1. 101
97 21.9% 18.7% 97 23.7% 8.3%
2. 101 12 1016,0759,2308,254 3,497 8,000
3. APP
4. 101 113 2012 65
5. 101 5 (DG SANCO) Ms. Paola Testori Coggi
68
37 1
6. 200 101 12 97% 99.7101 9 88 90 3-10 100 36,223 101 48,530 34.0% 100 9,708 101 15,433 59.0%
7. 101 9.8 2012 3 1,067
8. 49 6.5 9,706 100 101 1 2,800 79.5%
9. 98 101 114 2,621
69
() 1.
18 96 17.2% 101 10.9%
2. 97 174.4 100 173.7 0.4% 97 10 94.4 100 93.4 1.1% 105 10%
3. 92 96 41% 94 98 43% 2% 58% 60% 2%
4. 101 491 213.5 67 112.3 98.2 4,045 9,637 3,166 2,001 2 3,775 1,232 3,445
5. 101 1 1 3 1 3
70
HPV 2,020 3 94.1% 20.3% 1,348 3 98.5% 64%
6. 222 69
7. 101 37 101 47
8. 73 101 2 99 1 42% 98 39%3%
() 1.
100 2,954 101
71
101 6 8,021
2. 101 78 279 123 308 10 33 6,034
3. 101 45 45 90101 15,911 872 10,954
4. 101 1 12 11,880 693
5. 101 12 193 82
72
40 101 12 3,813 20 101 12 36 95,000101 302 17 101 161 373 31 565
6. 101 7
() 1.
101 749 34
73
2. : 100 547 538 98.4%
3. 907 889 () 307 1196
4. 101 100 11%
() 1. 5
1 4 101 : 404 132 137
2. 8 101 82 5,832
() 1. 71 (EV71) 101 3
1 2 102 1
74
2. (HPV) HPV
3. (RSV)
4. 10111 104
5. B TFDA 101 11
75
IND
6. 5-MTP 50%
7. 7 14,000 3
8. DBPR108 101 1 101 32
9.
76
10. 101 600
() 1.
65 (Toward Universal Coverage) WHA (2005)
77
1610 101 5 24 DG SANCO(WMA)(WHPA)
2. 101
3. APEC(2011 2012)APEC (HWG)(Health Policy Dialogue) 2012 APEC (APEC High-Level Meeting on Health and the Economy)(A Life Course Approach to Reducing the Economic Burden of Disease)Johnson & Johnson
4. APEC (Workshop on Cost-effectiveness of Strategies for Human Security) APEC
78
101 8 5. 2012 2012 Taiwan Health Forum
11 14 15722 42 Enrique T. Ona David Learmonth Masato Mugitani(APHA)(WFPHA)(APACPH)(WMA)WHO (UNDP)(SADC)(World Health Assemble, WHA)
() 1. 101
12
79
2. Non-communicable
Disesses-Global priorities and solutions
3. (1) 101 8 7
11
(2) (TaiwanIHA)(AMDA) 100 8 130 130 101 2 1
(3)
80
4.
100 6 26
101 8 1
WHO IHR 4 () 9
81
5. (1) ()
e-Health (2)
(3) 101 761
() 1. 101
20 121 101 8 8 50
2. 101 30 22
() 3
82
() 101711,153
101 101/03/01 Pham Van Thuc 6 101/04/0910
Esperanza Martinez 2
101/05/01 Hon. Jenniffer A. Gonzalez-Colon 6
101/07/25 Excmo. Lic. Gudy Rivera Estrada 7
101/07/27 Dr. Douglas Slater Mr. Andreas Wickham 2
101/09/11 Mr. Jean-Pierre Mazery 6
101/10/04 Erika Jurinova 6
101/11/13
Dr. Enrique T. Ona Dr. David Kabua Dr. Cecil B. Wilson Dr. Antonyia Parvanova 2012 24
101/11/15 David Learmonth
101/12/28 Ms. Pia Kjaersgaard 4
101 368 441
83
104 93 106 26 6 9 71 1,153
() ISO
1. ISO 9001: 2008 101 11 9 BV Cert.
2. 101 ISO 9001
() 2011 3.1(GRI G3.1) 2011 1
84
2012 12 102 1 24
() 1. 1
2 3 2. 1 2 3
85
4 102 6 12 3
5
() 1.
2. 3. 1
call center
2 3 GTF-CCC(Global Task Force-Cancer Care and
Control) 4
() 1. 1
86
2 3 2. 1 2 3. 1 2
2
3 4
() 1. 2. 55 64 3.
4. 5.
6.
HPV 7.
87
() 1.
2. 3. CDC
EUROCAT 4. 5. Gastein European Health Forum
()
12 18 752
()
88
82 1 101 10 16 12 18
()
()
() 1.
89
2.
3. 101 12 3 102 3
() 1.
2.
3. 4. 102
5.
90
() 2143 1670
() 1.
2. 3. 4. 5.
()
()
91
1.
2. IDS
3. (101-105 )
4.
() 1.
2. 102
()
92
1. 4.91%
105
2.
3.
() 1.
2.
() DRG
93
1. DRG
2.
() 1.
2. 73
3. () 1 3 6 4 5 4 6 2 10 (1)
94
(2)(3)(4)(5)(6) 102 2 22
() 102 1 1 102
1.
2.
3. NGO
4.
95
() 1.
()102 2
2.
3. 102 20 103 40
4.
()
() 1.
2.
3. 4.
96
100% 5.
() 1. 71
2. 71
()
()
() 104 PCV (ACIP)
97
() (DMF)
()
()
1.
2.
98
()
1.
2.
()
()
()
99
()
() 1. 102 2.
() 1.
2.
100
3.
() 1.
2.
() 1.
2.
()
101
() ()
()
()
()
() () ()
()
() () () () ()
102
82 1